Версия для слабовидящих:
Размер шрифта:
a
a
a

Tomsk hosted the 22nd Charles Heidelberg Symposium on Cancer Research

  • Main
  • News
  • Tomsk hosted the 22nd Charles Heidelberg Symposium on Cancer Research

The Charles Heidelberger Symposium is held annually in different countries and gathers the most representative community of well-known oncologists of the world in the field of biomedicine. In Tomsk, this Symposium was held for the first time and was jointly organized by Tomsk National Research Medical Center and National Research Tomsk State University.

The 22nd International Charles Heidelberg Symposium on Cancer Research was held on 17-19 September, 2018 in Tomsk. It was organized by Tomsk National Research Medical Center of Russian Academy of Sciences and National Research Tomsk State University. Prominent scientists from universities and clinics of Russia, the USA, Israel, Germany, France and other countries attended this Symposium. They presented latest achievements in the field of tumor development and discussed new approaches to the prevention, diagnosis and treatment of cancer.

“Cancer and cardiovascular diseases are the leading causes of death in Russia and in the world. According to statistics, every year, 7.5 million people around the world die from cancer, therefore, research on this issue is of great social importance"- said Prof. Nadezhda Cherdyntseva, Corresponding Member of the Russian Academy of Sciences, Head of the Laboratory of Molecular Oncology and Immunology of Cancer Research Institute of Tomsk National Research Medical Center, Leading Researcher of the Laboratory of Translational Cellular and Molecular Biomedicine of Tomsk State University.

This Symposium lasted for three days. The participants of the Symposium discussed etiology and epidemiology of cancer, molecular carcinogenesis, signaling mechanisms of tumor cells, tumor- microenvironment interaction, tumor immunology, etc. Scientists also discussed the problems of translating the results of basic research findings into routine clinical practice.

Dr. Joseph R. Landolph, Jr., Secretary, Chief Financial Officer, and Member of the Board of Directors, The Charles and Patricia Heidelberger Foundation for Cancer Research, and Associate Professor of Microbiology, Immunology, and Pathology and Member,USC/Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, Los Angeles, California, USA) submitted his oral presentation titled «Scientific Career of Professor Charles Heidelberger, The Charles and Patricia Heidelberger Foundation for Cancer Research and the International Charles Heidelberger Symposia for Cancer Research», which highlighted outstanding scientific achievements of the famous scientist in the field of oncology.

His lecture titled "Insoluble Ni+2 Compounds Induce Gene Amplification".

Gene Silencing, Disrupt 15 Signal Transduction Pathways, Induce Differential Expression of 144 Genes, and Cause Morphological, A. I., and Neoplastic Transformation of C3H/10T1/2 Mouse Embryo Cells” was devoted to the study of the mechanisms of carcinogenesis under the influence of nickel compounds in hazardous industries in order to develop novel approaches to cancer prevention.

The problem of chemical carcinogenesis was also discussed by Prof. Max Costa, (Dept. of Environmental Health, School of Medicine, New York University, New York, USA) in his talk titled «Nickel and Arsenic-Induced Epigenetic Effects During Neoplastic Cell Transformation».

Prof. Gloria M. Calaf, (Institute de Alta Investigacion, Universidad de Tarapaca, Arica, Chile, and Center for Radiological Research, Columbia Univ. Medical Center, New York, USA) gave a talk on carcinogenicity of environmental substances as parathion and malathion in breast carcinogenesis.

Prof. Wei Li, (Dept. of Dermatology and USC/Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, California, USA) in his lecture titled «Targeting Tumor-Secreted Heat Shock Protein-90alpha (Hsp90α) in Triple Negative Breast Cancer» raised the problem of personalized therapy.

Among the invited speakers, who submitted their research at the Symposium, there was Professor Alexis Gautreau, PhD, Head of the Department of Biology of the Polytechnic School, Principal Investigator of the National Center for Scientific Research of France, the author of more than 70 publications in top international journals (Nature, Science, etc.). He is a well-known scientist in the field of studying the mechanisms of tumor cell migration, invasion and metastasis, the major cause of death from cancer.

His colleague, Dr. Cécile Gauthier-Rouvière, from France (CRBM, CNRS) gave a lecture titled “Flotillin upregulation, a marker of poor prognosis, promotes an epithelial to mesenchymal transition and invasion”.

Professor Evgeny Imyanitov, Corresponding Member of the Russian Academy of Sciences from St. Petersburg, shared his experience relating to hereditary diseases associated with an increased risk of cancer. There are about 30 hereditary syndromes associated with the development of malignant tumors and up to 100 genes, whose participation in the development of malignant tumors has been proven. Evgeny Imyanitov was the first in Russia to organize a laboratory for molecular genetic testing of hereditary genetic disorders that lead to the development of cancer. Under his supervision, for the first time, previously unknown congenital mutations responsible for the development of breast cancer in women of European origin were discovered.

Professor Karl Heinrich Link, Head of Surgical Center and Asklepios Tumor Center, Asklepios Paulinen Klinik, Wiesbaden, Germany, the leading oncologist in the field of abdominal surgery, pointed to the increase in effectiveness of treatment for patients with inoperable liver cancer, multimodal approaches to treatment of colon and rectal cancers and personalized treatment of patients with colorectal cancer. He gave oral presentation titled «Colon and Rectal Cancer Are Different Tumor Entities According to Epidemiology, Carcinogenesis, Molecular and Tumor Biology, Surgery, and Multi-Modal Therapy, Quality of Results, and Primary and Secondary Prevention».

Dr. Robert Ladner (CEO, CV6 Therapeutics and Associate Professor, Dept. of Biochemistry, Queen’s University, Belfast, Ireland, United Kingdom) in his lecture titled «Inhibitors of dUTPase Enhance the Cancer Chemotherapeutic Activity of 5-Fluoro-Uracil» reported on the novel approaches to chemotherapy using already known chemotherapy drugs.

Professor David Аnn from USA (Department of Diabetes Complications and Metabolism, Diabetes and Metabolism Research Institute, City of Hope Comprehensive Center, Beckman Research Institute, Duarte, California, USA) is a co-head of the international program "Molecular and cellular biology of cancer." He is a co-author of the guidelines for the use and interpretation of assays for monitoring of autophagy (3rd edition). He has more than 150 publications with more than 7000 citations. Dr. Ann presented a report on the possibility of metabolic correction of malignant risk "Integrating Arginine Restriction and Tumor Biology".


Prof. Mikhail Krasilnikov, Head of the Institute of Carcinogenesis, N. N. Blokhin National Medical Research Centre of Oncology, Moscow, gave a lecture titled «Cell-Cell Interactions and the Formation of the Resistant Phenotype of Tumor Cells». He reported on the mechanisms of tumor resistance to hormone therapy.

His colleagues Prof. Мarianna Yakubovskaya and Antonina Alexandrova from Institute of Carcinogenesis, N. N. Blokhin National Medical Research Centre of Oncology (Moscow, Russia) also gave their oral presentations.

Dr. Anna Kudryavtseva from Moscow Engelhardt Institute of Molecular Biology, Russian Academy of Sciences gave a lecture titled «Molecular pathology of carotid body tumor».

Our Russian guests from Novosibirsk, Prof. Lyudmila Gulyaeva, Prof. Sergei Kovalenko and Prof. Elena Rykova gave oral presentations on molecular-genetic abnormalities in cancer progression and markers in personalized drug therapy.


The hosts of the Symposium, scientists of Tomsk National Research Medical Center and Tomsk State University, such as Prof. E.L. Choynzonov, Prof. V.I. Chernov, Prof. L.A. Kolomiets, Prof. E.M. Slonimskaya, Prof. I.V. Kondakova, N.V. Litvyakov, E.V. Denisov also submitted their interesting oral presentations.

“Such conferences make it possible to unite the scientific competences and resource bases of the entire world community"- said Yuliya Kzhyshkovska, Head of the Institute of Biomedicine of the TSU. “Charles Heidelberger Symposium is traditionally the platform that promotes the emergence of professional contacts, gives impetus to the emergence of new interesting ideas and research projects. We hope that the symposium will contribute to the solution of one of the most pressing problems of mankind - the fight against cancer”.

Within the framework of the school "Fundamentals of creating new approaches to diagnosis, prognosis and treatment of cancer" the participants of the Symposium shared their experience with young scientists. Practicing oncologists, as well as clinicians, who work closely with oncologists, could improve their skills.

The annual symposium of oncologists was held in Russia for the second time. In 2016, Moscow became the venue for it, and in 2018 the Organizing Committee chose Tomsk National Medical Center of the Russian Academy of Sciences and Tomsk State University as a venue for meeting leading oncologists, who established a joint scientific laboratory and successfully cooperate in the field of biomedicine.